newsroom /

Milan, Italy May. 10, 2022

KLISBio to present SILKBridge for peripheral nerve repair and its innovative silk-based tissue-engineered technology platform at 2022 Bio€quity Europe

Milan, Italy (May 11, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 Bio€quity Europe. 2022 Bio€quity Europe will be held May 16 -18, 2022 in Milan – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, will be presenting on Wednesday, May 18 at 9:30 am CEST in Isozaki room at the Melià Hotel in Milan.

Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge, KLISBio’s first product in pipeline for peripheral nerve repair.

SILKBridge is an absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The tissue engineered technology at the core of SILKBridge merges a deep-rooted cultural tradition and know-how with the most advanced technologies creating a highly purified material required for biomedical applications, without the need for chemical cross-linking reactions that alter silk fibroin. KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.

“KLISBio’s ambition is to offer the market a silk-based multidisciplinary technology platform able to generate products and solutions acting as a support for tissue regeneration. KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. We believe we can compete with existing players and revolutionize the regenerative medicine space.”, said Antonio Alessandrino, CTO and Founder at KLISBio.

KLISBio is powered by a group of world leaders in MedTech including Gabriele Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer; Giuliano Freddi, Chief Scientific Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades of experience in global healthcare. In addition to the strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space.

About KLISBio:

KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.